The Glimpse Group, Inc.
20.7.2021 14:31:37 CEST | ACCESS Newswire | Press release
Foretell Reality, a Glimpse subsidiary company, to Develop VR Experiences and Tools to Support North-Star Care's Tele-Health Substance Use Disorder Program
NEW YORK, NY / ACCESSWIRE / July 20, 2021 / Foretell Reality, a wholly-owned subsidiary of The Glimpse Group, Inc. (NASDAQ:VRAR; "Glimpse"), and a provider of social Virtual Reality (VR) multi-person spaces, collaboration and interpersonal interaction, today announced a multiyear, six figure, software and services engagement with telehealth medical treatment provider North-Star Care (NSC).
Foretell Reality (https://foretellreality.com/) leverages VR to enhance interpersonal experiences in professional settings, including for therapy and mental support, soft skills practice and development, remote business and creative collaboration.
North-Star Care (https://north-star.care/) provides tele-health medical addiction treatment through constantly evolving treatment protocols that include AI/machine learning, medication, VR peer support, wearable assessment, drink substitution, nootropic and nutraceutical supplements. NSC is disrupting the paradigm and changing how people with alcohol use disorder (AUD) receive care on an ongoing basis while reducing barriers for participation and recovery.
Foretell and NSC will develop a robust roadmap of VR experiences and tools to be integrated with NSC's mobile application and administrative system, supporting biometric authentication, secured protocols, and by invitation-only sessions. This includes VR environments for support group and 1x1 sessions, customizable avatar representation, social interaction and activities (e.g. mindfulness exercises, games), shareable media (e.g. documents, 360 and 2D videos), and remote communication through spatial audio, and non-verbal cues (e.g. body movement, hand gestures). The companies will also conduct studies and customer focus groups to continually evolve and optimize the use of VR for treatment of alcohol use disorder through social engagement, guidance, and practice from anywhere.
Amanda Wilson, MD and CEO of NSC said, "We believe that VR technology will play a vital role in enhancing treatment of substance use disorder by providing an immersive and engaging tool for remote peer support and clinical guidance. As we look to disrupt traditional AUD treatment practices, our engagement with Foretell Reality provides the pathway to innovate and evolve our comprehensive, team based virtual treatment protocols to deliver a state-of-the-art medical program to help our patients".
Dror Goldberg, General Manager of Foretell Reality and Glimpse's VP Product commented, "NSC offers an innovative virtual alcohol treatment program, and we are thrilled to work with their highly-experienced team to address this important mission. By utilizing Foretell Reality's platform to deploy and manage specialized VR experiences, clinicians and participants have access to the unique capabilities that VR now allows in order to enhance the efficacy of therapy, support and mentoring techniques for those suffering from AUD. Foretell's immersive experiences provide a tangible group presence, while reducing traditional therapy barriers through anonymity and ease of access from the comfort of one's home. We look forward to a successful and long-term engagement with North-Star Care."
About Foretell Reality
Foretell Reality is a social virtual reality platform that supports many different types of avatars with varying degrees of realism and expression for different use cases including VR therapy and support, soft skills training, and business collaboration. For more details: https://foretellreality.com/
About North-Star Care
North-Star Care is a telehealth alcohol treatment program that is comprehensive, multidisciplinary, and personalized for each patient. A virtual alcohol treatment program that is an alternative to rehab. We are the most comprehensive, team-based medical program available. For more details: https://north-star.care/
About The Glimpse Group, Inc.
The Glimpse Group (NASDAQ: VRAR) is a diversified Virtual and Augmented Reality platform company, comprised of multiple VR and AR software & services companies, and designed with the specific purpose
of cultivating companies in the emerging VR/AR industry. Glimpse's unique business model simplifies challenges faced by VR/AR companies and creates a robust ecosystem, while simultaneously providing investors an opportunity to invest directly into the emerging VR/AR industry via a diversified platform. For more information on The Glimpse Group, please visit www.theglimpsegroup.com
Safe Harbor Statement
This press release does not constitute an offer to sell or a solicitation of offers to buy any securities of any entity. This press release contains certain forward-looking statements based on our current expectations, forecasts and assumptions that involve risks and uncertainties. Forward-looking statements in this release are based on information available to us as of the date hereof. Our actual results may differ materially from those stated or implied in such forward-looking statements, due to risks and uncertainties associated with our business. Forward-looking statements include statements regarding our expectations, beliefs, intentions or strategies regarding the future and can be identified by forward-looking words such as "anticipate," "believe," "could," "estimate," "expect," "intend," "may," "should," and "would" or similar words. All forecasts are provided by management in this release are based on information available at this time and management expects that internal projections and expectations may change over time. In addition, the forecasts are entirely on management's best estimate of our future financial performance given our current contracts, current backlog of opportunities and conversations with new and existing customers about our products and services. We assume no obligation to update the information included in this press release, whether as a result of new information, future events or otherwise.
Foretell Reality Contact:
Dror Goldberg
General Manager
dror@foretellreality.com
Glimpse Contact:
Maydan Rothblum
CFO & COO
The Glimpse Group, Inc.
maydan@theglimpsegroup.com
Investor Relations:
Mark Schwalenberg, CFA
MZ Group - North America
312-261-6430
Glimpse@mzgroup.us
www.mzgroup.us
SOURCE: The Glimpse Group, Inc.
View source version on accesswire.com:
https://www.accesswire.com/656063/The-Glimpse-Group-and-North-Star-Care-Announce-a-Multiyear-Virtual-Reality-Software-and-Services-Engagement
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Datavault AI Chief Executive Officer and President Issues Letter to Stockholders Highlighting 2025 Accomplishments and Outlook for 20265.2.2026 12:00:00 CET | Press release
Datavault AI signed $49M of Tokenization and Technology Licensing agreements in Q4'25 that impact FY2025 and FY2026 Revenue. Revenue: Datavault AI expects at least $30 million in revenue for FY2025, compared to $2.7 million in FY2024. This represents an increase of more than 1,000% growth in our revenue over 2024. The Company continues to expand to drive substantial near- and long-term accretion to our cash flows and earnings with a revenue target for 2026 of at least $200 million. PHILADELPHIA, PENNSYLVANIA / ACCESS Newswire / February 5, 2026 / Datavault AI Inc. (NASDAQ:DVLT) ("Datavault AI" or the "Company"), a leader in data monetization, credentialing, digital engagement and real-world asset (RWA) tokenization technologies, today issued a letter from Nathaniel Bradley, its Chief Executive Officer, to its stockholders highlighting the Company's accomplishments in 2025 and its outlook for 2026. A MESSAGE FROM OUR CHIEF EXECUTIVE OFFICER Dear Datavault AI Stockholders, I would like t
AGFA HealthCare Named Best in KLAS(R) 2026 Across Three Enterprise Imaging Segments in the United States4.2.2026 15:45:00 CET | Press release
Industry recognition for the third consecutive year reinforces AGFA HealthCare's clinician-first commitment, and leadership in empowering connected, high-performance imaging environments MORTSEL, BE / ACCESS Newswire / February 4, 2026 / AGFA HealthCare today announced that it has been named Best in KLAS® 2026 across three Enterprise Imaging segments in the United States, with two awards earned for the second consecutive year, underscoring the company's continued leadership in delivering clinician-first imaging solutions trusted by healthcare organizations worldwide. The recognition comes as KLAS Research marks its 30th anniversary, celebrating three decades of amplifying the voice of healthcare providers through independent, data-driven insights. AGFA HealthCare's Best in KLAS distinctions reflect strong customer validation of its Enterprise Imaging platform - designed to empower clinicians to stay in their flow, reduce complexity across imaging workflows, and enable confident clinica
Preservica Redefines Digital Preservation with Powerful Built-In AI Tools4.2.2026 15:00:00 CET | Press release
OXFORD, UK and BOSTON, MA / ACCESS Newswire / February 4, 2026 / Preservica, the leader in AI-powered Active Digital Preservation™, today announced the rollout of integrated, human-centered AI tools and flexible AI Credits across its product editions. These new features make AI assistance a seamless part of everyday archival workflows, empowering organizations of all sizes to safely adopt AI and scale its use as their needs grow. "With the sheer volume of digital content in backlogs and being created daily, using AI to assist in archival tasks has now become essential" says Stuart Reed, Chief Product Officer at Preservica "Seamlessly integrating human-centered AI tools across our product editions turns AI for Digital Preservation into reality - enabling organizations of all sizes to accelerate routine work, cut backlogs and enhance discovery." Developed in collaboration with Preservica's user community and refined through the company's highly rated AI Workshop series, these embedded to
Karbon-X Files Quarterly Report on Form 10-Q Highlighting Strong Revenue Growth and Commercial Scale4.2.2026 15:00:00 CET | Press release
CALGARY, AB / ACCESS Newswire / February 4, 2026 / Karbon-X Corp. (OTCQX:KARX) ("Karbon-X" or the "Company"), a vertically integrated climate solutions company, today announced that it has filed its Quarterly Report on Form 10-Q for the six months ended November 30, 2025. The filing highlights continued momentum in Karbon-X's commercial operations, driven by significant revenue growth and the expansion of its global carbon activities across both compliance and voluntary markets. "Over the past several quarters, we transformed Karbon-X from a developing platform into a scaled, revenue-generating global operator," said Chad Clovis, Chief Executive Officer of Karbon-X Corp. "Revenue increased to $56.5 million (USD), compared to $1.3 million (USD) in the prior-year period, reflecting the strength of our commercial strategy and the growing demand for high-integrity carbon solutions. As we continue to invest in scaling our operations, our expanding global footprint, improved profitability, a
Axon Neuroscience's Immunotherapy Selected for a Landmark Combination-Therapy Alzheimer’s Clinical Trial in US, Supported by a USD 151 Million Grant4.2.2026 14:00:00 CET | Press release
Axon Neuroscience's active tau immunotherapy AADvac1 has been selected as the first tau-targeted therapy to enter a groundbreaking U.S. Alzheimer's disease phase 2 clinical trial (supported by a USD 151 million grant) and, simultaneously, a new platform trial for progressive supranuclear palsy (PSP) (supported by a USD 75 million grant) SAN FRANCISCO, CA / ACCESS Newswire / February 4, 2026 / Axon Neuroscience, a global leader in immunotherapy for human neurodegenerative diseases with an internationally recognized scientific team, announces the achievement of two historic milestones with the potential to significantly influence the future treatment of Alzheimer's disease and progressive supranuclear palsy (PSP): 1. AADvac1 Selected as the First Tau Therapy in the Phase 2 Alzheimer's Tau Platform (ATP) Combination-Therapy Trial An independent panel of leading U.S. scientific and clinical experts selected AADvac1 as the first therapy targeting pathological tau protein to be evaluated in
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom